34 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
manufacturing activity, and lower personnel costs due to fewer research and development headcount compared to prior year.
Administrative expenses … December 31,
(in USD thousands)
Research and development expenses
Administrative expenses
Net impairment losses
Other income
Other (losses)/gains - net
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
.
1.18. “Develop” or “Development” shall mean to conduct any non-clinical or clinical drug research or development activities, whether before or after
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
as of December 31, 2022. The decrease was mainly due to ongoing research and development (R&D) costs associated with the Company’s clinical drug programs … )
Research and development expenses
Administrative expenses
Other income
Other gains - net
Operating loss
Finance income
Finance cost
Finance income - net
Net
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
Statements of Loss
For Six Months Ended June 30,
Notes
RMB’000
USD’000
Note 2
Research and development expenses
Administrative expenses
Other … in the interim condensed consolidated statements of loss:
Six Months Ended June 30,
RMB’000
Research and development expenses
Administrative expenses
7.Other
6-K
EX-99.1
ilcho57unp3855w3
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
ubnuyoel2uffqo
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
EX-99.1
8fa012uxar 2exk4s
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
3329wqsr
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
k56wz0cf6e2svgz
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
6-K
EX-99.1
4wnf90cr
10 Jun 22
Current report (foreign)
6:05am
F-3/A
3eqy6
20 May 22
Shelf registration (foreign) (amended)
6:54pm
F-3
wb26b5ei0
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
rovk5g 4q6j
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
EX-4.12
u4xjvy4
31 Mar 22
Annual report (foreign)
4:33pm
20-F
6nw7cd7e 20r2xex9wse
31 Mar 22
Annual report (foreign)
4:33pm
6-K
oin98h2lo a71nhg
1 Mar 22
Current report (foreign)
4:16pm
6-K
EX-99.1
y9jd3vu6wu1p hw8
16 Feb 22
Current report (foreign)
4:01pm
6-K
EX-99.1
ktlekvo
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm